Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 6

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 6
---
 and its subsidiaries.

For investors outside the United States: We have not, and the underwriters have not, taken any action to permit this offering, or to permit the possession or distribution of this prospectus, in any jurisdiction where action for that purpose is required, other than the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to the offering of the Depositary Shares and the distribution of this prospectus outside of the United States.

| 1 |

<div align='center'>PRESENTATION OF FINANCIAL INFORMATION AND OTHER INFORMATION</div>

Our financial statements are
prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board and
adopted by the European Union. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical
figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.

We prepare our consolidated
financial statements in British pounds sterling. Except as otherwise stated, all monetary amounts in this prospectus are presented in
British pounds sterling.

In this prospectus, unless
otherwise specified or the context otherwise requires:

| · | “$” and “U.S. dollar” each refer to the United States dollar (or units thereof); 
 and                                                                              |

| · | “£,” “pence” and “p” each refer to the British pound sterling 
 (or units thereof).                                           |

On March 27, 2023, following shareholder approval at a general meeting,
we effected a one-for-20 reverse stock split of our Ordinary Shares, and our consolidated Ordinary Shares began trading on AIM, a market
operated by the London Stock Exchange plc, or AIM, on a split-adjusted basis as of such date. No fractional shares were issued in connection
with the reverse stock split. At the same general meeting, our shareholders approved the cancellation of admission of our Ordinary Shares
on AIM and this cancellation became effective on April 26, 2023.

Concurrently with the reverse stock split, and in order to continue
meeting The NASDAQ Stock Market LLC’s, or NASDAQ, minimum 500,000 publicly held shares requirement pursuant to Rule 5550(a)(4),
on March 27, 2023 we effected a ratio change in the number of Ordinary Shares represented by the Depositary Shares from 25 Ordinary Shares
per Depositary Share to five Ordinary Shares per Depositary Share.

On June 14,